Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Lilly makes amends with Adocia in $570M diabetes deal

Eli Lilly is buying back into Adocia's pitch for a fast-acting insulin, reversing an earlier decision and signing a collaboration deal worth up to $570 million.

Lilly's Elanco disputes local paper's allegations of unsafe pet meds

A war of words has broken out over the past week between Eli Lilly's Elanco animal health division and the company's hometown newspaper, the Indianapolis Star. At issue is an overriding question that weighs on the minds of pet owners worldwide: Are medications for dogs and cats really safe?

Lilly's blockbuster hopeful Cyramza nabs key new use in lung cancer

The plan for Eli Lilly's Cyramza has always been to rack up a string of approvals to vault the drug into blockbuster territory. As of Friday, the Indianapolis drugmaker is one step closer to achieving that goal.

Lilly and Incyte's oral arthritis drug aces its first Phase III test

A new rheumatoid arthritis pill from Eli Lilly and Incyte beat out placebo in a pivotal trial, the first late-stage success for a drug the companies hope can carve out a space in a crowded market.

Lilly inks a $440M deal for Zosano's osteoporosis therapy

Eli Lilly has stepped in to ink a worldwide license on Zosano Pharma's recipe for parathyroid hormone 1-34 dubbed ZP-PTH, which is delivered via its microneedle patch system to treat osteoporosis.

After numerous setbacks, Eli Lilly mounts another pivotal assault on Alzheimer's

Eli Lilly's never-say-die strategy for Alzheimer's has inspired another high-risk campaign in the clinic. The shrinking pharma giant--about to be bumped from the top 10 by a growing Actavis--has launched its pivotal Phase II/III study of its BACE drug for Alzheimer's, newly partnered with AstraZeneca.

The top 10 FierceBiotech stories of 2014

In biotech, here are the top 10 news stories of the year so far, based on web traffic.

Will GLP market growth save Novo's Victoza from Lilly's new Trulicity?

When a new drug bursts upon an established drug class, the established players often wave away worries about market share. Sales for the whole class will grow, they say, because we'll have one more company on the street promoting it. And when it comes to Eli Lilly's Trulicity, the brand-new GLP-1 diabetes treatment, even Lilly says so.

New numbers back old meme: Pharma does spend more on marketing than R&D

The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.

Two more guilty pleas in spectacular burglary of Lilly warehouse

Two more men have pleaded guilty to the daring burglary of drugs from an Eli Lilly warehouse in Connecticut in 2010. Yosmany Nunez and Alexander Marquez, both of Florida, pleaded guilty this week, according to NBC.